Skip to main content

Table 1 Baseline Characteristics: HbA1c ≥ 7 Cohort

From: Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis

 

MTX (N = 361)

TNFi (N = 254)

Metformin (N = 2144)

SMD TNF vs MTX

SMD Met vs MTX

Mean age, years (SD)a

45 (3)

45 (3)

45 (3)

0

0

Male sex (%)b

37%

32%

40%

−0.15

0.08

Baseline HbA1c

8.29

8.31

8.41

−0.02

0.07

Comorbidities, N (%)

 Anemia

55(15%)

29 (11%)

232 (11%)

−0.11

−0.11

 Angina

59 (16%)

28 (11%)

227 (11%)

−0.15

− 0.15

 Anxiety

35 (10%)

39 (15%)

375 (17%)

0.15

0.21

 Asthma

73 (20%)

48 (19%)

388 (18%)

−0.03

− 0.05

 CAD

121 (34%)

60 (24%)

544 (25%)

−0.22

−0.20

 CHF

49 (14%)

28 (11%)

251 (12%)

−1.46

−0.16

 CKD

103 (29%)

56 (22%)

360 (17%)

−0.28

−0.52

 COPD

56 (16%)

48 (19%)

393 (18%)

0.08

0.05

 Cardiomyopathy

19 (5%)

9 (4%)

88 (4%)

−0.25

−0.25

 Other CTD

21 (6%)

12 (5%)

67 (3%)

0.20

0.71

 Depression

71 (20%)

65 (26%)

503 (23%)

0.26

0.14

 DM retinopathy

64 (18%)

42 (17%)

29 (1%)

−0.06

−1.37

 Hypertension

316 (88%)

217 (85%)

1807 (84%)

−0.03

−0.05

 Hypothyroidism

112 (31%)

88 (35%)

671 (31%)

0.12

0.00

 Dyslipidemia

312 (86%)

225 (89%)

1825 (85%)

0.03

−0.01

 Inflammatory bowel disease

9 (2%)

12 (5%)

44 (2%)

0.90

0.00

 Liver disease

88 (24%)

64 (25%)

408 (19%)

0.04

−0.24

 Myocardial infarction

23 (6%)

8 (3%)

36 (2%)

−0.71

−1.00

 Obesity

98 (27%)

72 (28%)

629 (29%)

0.04

0.07

 Psoriasis

43 (12%)

81 (32%)

154 (7%)

0.84

−0.54

Baseline diabetes medications, N (%)

316 (88%)

232 (91%)

2144 (100%)

0.03

0.13

Baseline MTX, N (%)

–

128 (50%)

274 (13%)

n/a

n/a

Baseline TNFi, N (%)

36 (10%)

84 (33%)

214 (10%)

0.96

0.00

Baseline Steroidsc, N (%)

152 (42%)

100 (39%)

394 (18%)

−0.07

−0.75

Average baseline glucocorticoid dose, mean (SD)

6 (7)

6 (6)

5(7)

0

0.14

Duration btwn baseline and f/up HbA1c, mean # of days (SD)

241 (83)

237 (84)

201 (79)

0.05

−0.49

Duration btwn med start date and f/up HbA1c, mean # of days (SD)

173 (66)

166 (65)

168(66)

−0.11

−0.08

  1. N number of observations
  2. TNFi, MTX, and metformin groups are not mutually exclusive
  3. aIn the metformin group, one observation is missing for age
  4. bIn the metformin group, two unknown observations for sex were changed to missing
  5. cSix-month baseline period
  6. Abbreviations: CAD Coronary artery disease, CKD Chronic kidney disease, CTD Connective tissue disease (ICD9 code 710.9, not inclusive of SLE, sicca, or scleroderma), COPD Chronic obstructive pulmonary disease, CHF Congestive heart failure, DM Diabetes mellitus, HbA1c Hemoglobin A1c, MTX Methotrexate, SMD Standardized mean difference, TNFi Tumor necrosis factor inhibitor
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us